Targeted antibody, immune checkpoint blocker rein in follicular lymphoma
One drug attacks tumor cells directly, the other treats the immune
system by taking the brakes off T cell response. Together, they put half
of the patients with relapsed follicular lymphoma into complete
remission in a phase II clinical trial at The University of Texas MD
Anderson Cancer Center.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news